Ying Mu, PhD, DABT joined Zhongke Shanghai-Hong Kong (ZSHK) International Biotechnology Co., Ltd. as a Chief Scientific Officer in 2022. He is a board-certified toxicologist with nine years of experience at FDA in the Center for Devices and Radiological Health (CDRH) and the Center for Drug Evaluation and Research (CDER). Dr. Mu was formerly Toxicologist and Principal Investigator in the Division of Biology, Chemistry, and Materials Science, Office of Science and Engineering Laboratories (CDRH), and Pharmacology and Toxicology Reviewer in the Division of Special Pathogen and Transplant Products, Office of New Drugs (CDER). Prior to his FDA career, he was a Research Assistant Professor in the School of Pharmacy at the University of Pittsburgh, where he worked on nuclear receptors, mediated gene regulation, mechanism of action in efficacy and safety, and new molecule entity identification and development.
Dr. Mu is a highly-respected toxicologist, acting as an expert consultant for several US and Chinese companies, with more than 25 years of life science research experience and a broad array of knowledge, including biomarkers, toxicology, pharmacology, PK/PD, immunology, cell therapy, stem cell, tissue engineering, biomaterials, biocompatibility, medicine, animal modeling, molecular-cell biology, mechanism of action, drug-device combination, pre-market risk assessments, post-market safety evaluation, the filing and the regulation. He has published 28 peer-reviewed articles, and holds a PhD in Medicine from Gunma University, Japan. He is fluent in Japanese, English and Chinese.